Revenue
2018
2019
2020
2022
2023
2024
2025
Black Diamond Therapeutics, Inc. (BDTX)
Price$2.12Cached quote
Net income
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2018
2019
2020
2021
2022
2023
2024
Total cash / debt
CashTotal debt
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $70.0M | $0 | $0 | $0 | — | $0 | $0 | $0 |
| Research & development | $33.6M | $51.3M | $59.4M | $64.4M | $96.8M | $48.2M | $21.8M | $7.0M |
| Operating expenses | $57.5M | $78.8M | $86.5M | $92.8M | $126.9M | $69.6M | $29.3M | $8.9M |
| Operating income | $12.5M | −$78.8M | −$86.5M | −$92.8M | −$126.9M | −$69.6M | −$29.3M | −$8.9M |
| Operating margin | 17.89% | — | — | — | — | — | — | — |
| EBITDA | $12.8M | −$78.4M | −$86.0M | −$92.3M | −$126.7M | −$69.5M | −$29.3M | −$8.9M |
| EBITDA margin | 18.35% | — | — | — | — | — | — | — |
| Net income | $22.4M | −$69.7M | −$82.4M | −$91.2M | −$125.6M | −$67.3M | −$35.3M | −$8.9M |
| Net profit margin | 31.95% | — | — | — | — | — | — | — |
| Basic EPSper basic share | $0.39 | -$1.27 | -$1.88 | -$2.52 | -$3.47 | -$2.05 | -$16.99 | -$4.42 |
| Diluted EPSper diluted share | $0.39 | -$1.27 | -$1.88 | -$2.52 | -$3.47 | -$2.05 | -$16.99 | -$4.42 |
Owners
Reported shareholders
≈10.80%of listed shares
Versant Voyageurs I Parallel, L.P. / Versant Voyageurs I, L.P. / Versant Venture Capital VI, L.P. / Versant Vantage I, L.P.6.21M shares · Aug 28, 2024
View holders
| Holder | % owned |
|---|---|
Versant Voyageurs I Parallel, L.P. / Versant Voyageurs I, L.P. / Versant Venture Capital VI, L.P. / Versant Vantage I, L.P. | ≈10.80%6.21M shares |
Behbahani Ali | ≈7.92%4.55M shares |
NEA Management Company, LLC | 7.74%4.45M shares |
T. Rowe Price Investment Management, Inc. | 7.01%4.03M shares |
BlackRock, Inc. | 6.82%3.92M shares |
BIOTECH GROWTH N V / BB BIOTECH AG | ≈4.76%2.73M shares |
ACADIAN ASSET MANAGEMENT LLC | 4.09%2.35M shares |
VANGUARD CAPITAL MANAGEMENT LLC | 3.70%2.13M shares |
RENAISSANCE TECHNOLOGIES LLC | 3.42%1.96M shares |
Defilade Capital Management, L.P. | 2.92%1.67M shares |
DIMENSIONAL FUND ADVISORS LP | 2.38%1.37M shares |
GEODE CAPITAL MANAGEMENT, LLC | 2.12%1.22M shares |
Connor, Clark & Lunn Investment Management Ltd. | 1.90%1.09M shares |
AWM Investment Company, Inc. | 1.74%1M shares |
MARSHALL WACE, LLP | 1.56%896.6K shares |
BRIDGEWAY CAPITAL MANAGEMENT, LLC | 1.38%791.43K shares |
FMR LLC | 1.12%643.67K shares |
Balyasny Asset Management L.P. | 0.94%542.17K shares |
STATE STREET CORP | 0.91%525.01K shares |
BANK OF AMERICA CORP /DE/ | 0.72%413.52K shares |
Percentages use 57.45M shares of this listed class outstanding on Jun 30, 2026. ≈ compares the latest reported holding with a share total from a different date; it is not a confirmed current stake.
Gray completes the 100% scale. Reported positions may overlap; holders have different reporting dates.
Source: SEC Form 4 ↗Updated Sep 29, 2026 · Quarterly data
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Mar 19, 2025Form 4 | BIOTECH GROWTH N V +1TenPercentOwner | SellCommon Stock | 500.0K | $2.12 | $1.06M | 2.73M |
| Mar 19, 2025Form 4 | BIOTECH GROWTH N V +1TenPercentOwner | SellCommon Stock | 584.3K | $1.95 | $1.14M | 3.23M |
| Mar 19, 2025Form 4 | BIOTECH GROWTH N V +1TenPercentOwner | SellCommon Stock | 400.0K | $2.09 | $836.0K | 3.82M |
| Mar 19, 2025Form 4 | BIOTECH GROWTH N V +1TenPercentOwner | SellCommon Stock | 2.00M | $2.00 | $4.00M | 4.22M |
| Mar 19, 2025Form 4 | BIOTECH GROWTH N V +1TenPercentOwner | SellCommon Stock | 1.00M | $2.31 | $2.31M | 6.22M |